Lawmakers from both parties are seeking more information about regulators’ capacity to protect the U.S. drug supply, as foreign-made generic blood-pressure pills tainted with probable carcinogens continue to be recalled.
House Energy and Commerce Committee Chairman Frank Pallone, a New Jersey Democrat, and Oregon Representative Greg Walden, the panel’s top Republican, want details on the U.S. Food and Drug Administration’s ability to adequately inspect foreign and domestic pharmaceutical manufacturing facilities, according to documents provided to Bloomberg.
The lawmakers are seeking specific information regarding a recall of the drug valsartan that was manufactured by Chinese firmZhejiang Huahai Pharmaceutical Co. Ltd. They also want more details about a dispute between senior FDA staff and an inspector who visited one of the company’s plants where medication contaminated with the probable human carcinogen NDMA was first detected.
Print Page
Email to a Friend